Needham Maintains Buy on Conmed, Lowers Price Target to $97
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson maintains a Buy rating on Conmed (NYSE:CNMD) but lowers the price target from $106 to $97.

August 01, 2024 | 9:46 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst Mike Matson maintains a Buy rating on Conmed but lowers the price target from $106 to $97.
The maintained Buy rating suggests continued confidence in Conmed's performance, but the lowered price target indicates some caution about its short-term prospects. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100